NCT03063684 is a NA clinical trial of Fractional / Pixel CO2 Laser in Vaginal Atrophy, sponsored by Hadassah Medical Organization.

Who is sponsoring NCT03063684?

NCT03063684 is sponsored by Hadassah Medical Organization.

What drugs are being tested in NCT03063684?

Interventions in NCT03063684: Fractional / Pixel CO2 Laser.

What condition does NCT03063684 study?

NCT03063684 studies Vaginal Atrophy, Lichen Sclerosus.

Is NCT03063684 still recruiting?

NCT03063684 is currently completed. Last updated 6 August 2019.

Last reviewed 2019-08-06 · How we verify

NCT03063684

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus

Completed NA Last updated 6 August 2019

What this trial tests

NA trial testing Fractional / Pixel CO2 Laser in Vaginal Atrophy in 16 participants. Completed in 28 April 2019.

Timeline

1 September 2017

Primary endpoint
30 December 2018

28 April 2019

Quick facts

Lead sponsor	Hadassah Medical Organization
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	16
Start date	1 September 2017
Primary completion	30 December 2018
Estimated completion	28 April 2019
Sites	1 location across Israel

Drugs / interventions tested

Fractional / Pixel CO2 Laser

Conditions studied

Vaginal Atrophy — all drugs for Vaginal Atrophy →
Lichen Sclerosus — all drugs for Lichen Sclerosus →

Sponsor

Hadassah Medical Organization — full company profile →

Who can join

Adults 18 to 80, female only, with Vaginal Atrophy or Lichen Sclerosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will examine the effects of fractional/pixel CO2 laser treatment in vaginal atrophy and in vulvar lichen sclerosus by means of histological and immuno-histochemical characterization of the epithelial layers and markers of tissue aging. The tissue characterization will be performed by biopsies of the vaginal or vulvar tissue at three different points of time: prior to treatment, two weeks after the third and last treatment, and one year after the last treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

"Modified Schirmer Test" as an Objective Measurement for Vaginal Dryness: A Prospective Cohort Study.
Gabrieli D, Suissa-Cohen Y, Jaber S, Lev-Sagie A. · · 2022 · cited 6× · PMID 35328126 · DOI 10.3390/diagnostics12030574

Verify or expand the search:

Other recruiting trials for Vaginal Atrophy

Currently open trials in the same condition.

NCT05457972 — Postpartum Vaginal Estrogen for Breastfeeding Patients · Phase 4 · recruiting
NCT06028009 — PRP Injections for Genitourinary Syndrome of Menopause · NA · active not recruiting
NCT07024667 — Clinical and Molecular Study to Evaluate the Effect of the Pixel CO2 Laser (FemiLiftTM) for the Treatment of Vulvo-Vagin · NA · recruiting
NCT05335317 — Treatment of Vaginal Atrophy With Low Intensity Nanosecond Neodymium Laser · NA · recruiting
NCT04807894 — Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo · Phase 4 · recruiting

Other Hadassah Medical Organization trials

Trials by the same sponsor.

NCT07430358 — Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence · NA · not yet recruiting
NCT07429019 — Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind T · NA · not yet recruiting
NCT07393568 — The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometri · not yet recruiting
NCT07333430 — Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03063684 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hadassah Medical Organization
Last refreshed: 6 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03063684.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing